Docetaxel in Treating Patients With Advanced Cancer of the Cervix
Docetaxel in Treating Patients With Advanced Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
 they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients with
 advanced cancer of the cervix.
OBJECTIVES: I. Assess the antitumor activity of docetaxel as neoadjuvant chemotherapy in
 patients with locally advanced squamous cell carcinoma of the cervix. II. Assess the tumor
 response, toxic effect, and survival rate of this regimen in these patients.

 OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Treatment is repeated every 3
 weeks for 3 courses. Patients are followed every 3 months posttreatment.

 PROJECTED ACCRUAL: A total of 16-35 patients will be accrued for this study.
DISEASE CHARACTERISTICS: Histologically proven stage IIB, IIIA, IIIB, and IVA squamous cell
 carcinoma of the cervix Bidimensionally measurable disease No bilateral hydronefrosis

 PATIENT CHARACTERISTICS: Age: Any age Performance status: WHO 0-2 Life expectancy: At least
 12 weeks Hematopoietic: Hemoglobin at least 10 g/dL Leukocytes at least 4,000/mm3 Platelet
 count at least 75,000/mm3 Hepatic: Bilirubin less than 1.25 times upper limit of normal
 (ULN) AST less than 1.25 times ULN Renal: BUN less than 30 mg/dL AND Creatinine less than
 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Other: No prior or other concurrent
 malignancies, other than properly treated basal cell skin cancer

 PRIOR CONCURRENT THERAPY: Not specified